Shanghai Allist Pharmaceuticals Achieves Annual Production Capacity of 200 Million Fuzulatinib Mesylate Tablets

Deep News11-28

An investor inquired on the interactive platform regarding the production capacity of Fuzulatinib Mesylate tablets and the utilization rate of the two production lines in November.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) responded on November 28, stating that its wholly-owned subsidiary, Jiangsu Allist Pharmaceuticals, has obtained GMP compliance certification from the Jiangsu Provincial Medical Products Administration for a new production line with an annual capacity of 150 million Fuzulatinib Mesylate tablets. This approval, secured in July 2025, allows the subsidiary to commence production.

Combined with the existing production line capable of producing 50 million tablets annually, the company now has a total production capacity of 200 million Fuzulatinib Mesylate tablets per year. This expansion ensures stable product supply and supports growing market demand.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185038216?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-28 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185038216","market":"hk","top_or_hot":-1,"title":"Shanghai Allist Pharmaceuticals Achieves Annual Production Capacity of 200 Million Fuzulatinib Mesylate Tablets","media":"Deep News","content":"<p>An investor inquired on the interactive platform regarding the production capacity of Fuzulatinib Mesylate tablets and the utilization rate of the two production lines in November.</p>\n<p>Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) responded on November 28, stating that its wholly-owned subsidiary, Jiangsu Allist Pharmaceuticals, has obtained GMP compliance certification from the Jiangsu Provincial Medical Products Administration for a new production line with an annual capacity of 150 million Fuzulatinib Mesylate tablets. This approval, secured in July 2025, allows the subsidiary to commence production.</p>\n<p>Combined with the existing production line capable of producing 50 million tablets annually, the company now has a total production capacity of 200 million Fuzulatinib Mesylate tablets per year. This expansion ensures stable product supply and supports growing market demand.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Allist Pharmaceuticals Achieves Annual Production Capacity of 200 Million Fuzulatinib Mesylate Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Allist Pharmaceuticals Achieves Annual Production Capacity of 200 Million Fuzulatinib Mesylate Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-11-28 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>An investor inquired on the interactive platform regarding the production capacity of Fuzulatinib Mesylate tablets and the utilization rate of the two production lines in November.</p>\n<p>Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) responded on November 28, stating that its wholly-owned subsidiary, Jiangsu Allist Pharmaceuticals, has obtained GMP compliance certification from the Jiangsu Provincial Medical Products Administration for a new production line with an annual capacity of 150 million Fuzulatinib Mesylate tablets. This approval, secured in July 2025, allows the subsidiary to commence production.</p>\n<p>Combined with the existing production line capable of producing 50 million tablets annually, the company now has a total production capacity of 200 million Fuzulatinib Mesylate tablets per year. This expansion ensures stable product supply and supports growing market demand.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688578","symbol_name":"艾力斯","start_time":0,"source_url":"","article_id":"1185038216","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185038216","pubTimestamp":1764331272,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"An investor inquired on the interactive platform regarding the production capacity of Fuzulatinib Mesylate tablets and the utilization rate of the two production lines in November. Shanghai Allist...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688578":"艾力斯","BK0239":"医药制造"},"translate_title":"上海艾利斯特制药实现年产2亿片甲磺酸福祖拉替尼片产能","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688578":1},"content_text":"An investor inquired on the interactive platform regarding the production capacity of Fuzulatinib Mesylate tablets and the utilization rate of the two production lines in November.\nShanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) responded on November 28, stating that its wholly-owned subsidiary, Jiangsu Allist Pharmaceuticals, has obtained GMP compliance certification from the Jiangsu Provincial Medical Products Administration for a new production line with an annual capacity of 150 million Fuzulatinib Mesylate tablets. This approval, secured in July 2025, allows the subsidiary to commence production.\nCombined with the existing production line capable of producing 50 million tablets annually, the company now has a total production capacity of 200 million Fuzulatinib Mesylate tablets per year. This expansion ensures stable product supply and supports growing market demand.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185038216","isCrawlerRequest":true}